Novartis
NVS
$99.66
Share price
0.29%
Change (1 day)
12.39%
Change (1 year)
Categories
Novartis AG is a biotechnology and pharmaceutical company based in Basel, Switzerland. Novartis was formed in 1996 from a merger of the two Basel pharmaceutical and chemical companies Ciba-Geigy AG and Sandoz AG. Novartis is one of the largest pharmaceutical companies in the world with sales of USD 47.4 billion in 2019.
Novartis (NVS) - Total liabilities
Total liabilities on the balance sheet as of March 2023 : $60.09 B
According to Novartis's latest financial reports the company's total liabilities are $60.09 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Novartis - Total liabilities on balance sheet (from 2001 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | $58.03 B | -9.29% |
| 2021-12-31 | $63.97 B | -15.15% |
| 2020-12-31 | $75.39 B | 20.02% |
| 2019-12-31 | $62.81 B | -6.06% |
| 2018-12-31 | $66.87 B | 13.63% |
| 2017-12-31 | $58.85 B | 6.55% |
| 2016-12-31 | $55.23 B | 1.47% |
| 2015-12-31 | $54.43 B | -0.2% |
| 2014-12-31 | $54.54 B | 5.33% |
| 2013-12-31 | $51.78 B | -5.85% |
| 2012-12-31 | $54.99 B | 6.67% |
| 2011-12-31 | $51.55 B | -3.72% |
| 2010-12-31 | $53.54 B | 40.76% |
| 2009-12-31 | $38.04 B | 36.54% |
| 2008-12-31 | $27.86 B | 6.93% |
| 2007-12-31 | $26.05 B | -2.46% |
| 2006-12-31 | $26.71 B | 8.73% |
| 2005-12-31 | $24.56 B | 19.56% |
| 2004-12-31 | $20.54 B | 9.31% |
| 2003-12-31 | $18.79 B | 12.33% |
| 2002-12-31 | $16.73 B | 13.47% |
| 2001-12-31 | $14.74 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $110.57 B | 83.99% | 🇺🇸 USA |
 Pfizer PFE | $101.28 B | 68.54% | 🇺🇸 USA |
 Abbott Laboratories ABT | $37.53 B | -37.55% | 🇺🇸 USA |
 Sanofi SNY | $55.23 B | -8.10% | 🇫🇷 France |
 Merck MRK | $63.10 B | 5.00% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $62.39 B | 3.82% | 🇺🇸 USA |
 AstraZeneca AZN | $60.87 B | 1.29% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $58.57 B | -2.54% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | $35.31 B | -41.24% | 🇮🇱 Israel |